Conference Track

Antiretroviral Drug Resistance

Source: CCO Independent Conference Coverage of the 2008 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

No Virologic Benefit of Dose Escalation of PIs in Patients With Normalized Inhibitory Quotient ≤ 1
Maraviroc Failure in Treatment-Naive Patients in MERIT Trial: Role of Pretreatment Tropism Switches and Patient Nonadherence
Adding Tenofovir/Emtricitabine to Single-Dose Nevirapine Effective for Preventing Mother-to-Child HIV Transmission and Reduces Risk of Developing NNRTI Resistance
Presence of Y181C NNRTI-Resistant Minority Viral Variants at Baseline Associated With Increased Risk for Efavirenz Treatment Failure in Antiretroviral-Naive Patients in ACTG 5095
Exposure to HAART Through Breast Milk Attributes to Development of HIV-1 Drug-Resistance Mutations in Infected Infants
Improved Detection of HIV Tropism With Enhanced Phenotypic Tropism Assay
Genetic Correlates of Maraviroc Resistance Further Defined in MOTIVATE Virology Substudy
Clinical Cutoffs for Etravirine Susceptibility Defined
In TITAN Subanalysis, Fewer Virologic Failures, Primary PI Mutations Found in Patients Receiving Darunavir/Ritonavir vs Lopinavir/Ritonavir
Genotyping of Plasma HIV Serves as Accurate Surrogate for HIV Drug Resistance in Genital Secretions
SensiTrop Assay Demonstrates Low Sensitivity for Detection of Dual/Mixed or CXCR4 HIV-1 Variants in Treatment-Experienced Patients

Expert Analysis

Antiretroviral Drug Resistance

Faculty:

Eric S. Daar, MD
Daniel R. Kuritzkes, MD
Andrew R. Zolopa, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe new data on strategies to reduce drug resistance associated with antiretroviral therapy for prevention of mother-to-child HIV transmission
Discuss recent findings on the impact of minority variants on virologic response to NNRTI-based regimens
Summarize new data on novel approaches to evaluate viral tropism
Cite recent insights into resistance from studies of maraviroc, darunavir/ritonavir, lopinavir/ritonavir, and etravirine

CREDIT INFORMATION

Release Date: March 28, 2008

Expiration Date: March 27, 2009

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing contact hours

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.